Prevatex Corporate Presentation – November 2023

Take a look at our latest presentation.

Prevatex Shareholder Newsletter – November 2023

Click through to view the November Shareholder Newsletter.

Prevatex Shareholder Newsletter – May 2023

Click through to view the May Shareholder Newsletter.

Prevatex Shareholder Newsletter – December 2022

Click through to view the December Shareholder Newsletter.

Carriage of Prevotella by pregnant mothers protects against food allergy in the child at one year of age – data from the Barwon Infant Study

Click through to view the publications.

Increased abundance of Prevotella in children at one year associated with reduced behavioural problems at 2 years of age – data from the Barwon Infant Study

Click through to view publications.

Abundance of Prevotella in the gut microbiota is associated with reduced allergy – data from other studies

Click through to view the publications.

The abundance of Prevotella in the gut microbiota is associated with improved cardio-metabolic health – data from large population-based studies

Click through to view the publications.

Prevatex Shareholder Newsletter – April 2022

Click through to view the April Shareholder Newsletter.

Prevatex has signed a supply and licence agreement with Ipromea

Click through to view the details of this important commercial milestone.